PhotoCure's acne study shows reduction in inflammatory lesions

By Elaine Rigoli

Tampa, Fla., Aug. 18 - PhotoCure ASA said results from an acne study showed a 54% reduction in the number of inflammatory lesions in the MAL-treated area and 20% reduction in the placebo-treated area.

The company said the results show that MAL PDT is an efficacious treatment for moderate-to-severe acne and that futher studies are warranted.

The study is a blinded, randomized, placebo-controlled trial comparing PhotoCure's patented MAL cream to a placebo cream for the treatment of moderate-to-severe facial acne in 30 patients.

PhotoCure is an Oslo, Norway-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.